Related Experiment Video
Updated: May 29, 2026

Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
Dystrophic epidermolysis bullosa: two case reports
Sorina Dănescu1, Simona Senilă, Luminiţa Leluţiu
1Department of Dermatology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Insights
Molecular diagnosis definitively identifies mutations causing dystrophic epidermolysis bullosa (DEB). This genetic investigation links patient phenotypes to genotypes, advancing understanding and treatment for DEB.
Area of Science:
- Genetics
- Dermatology
- Molecular Biology
Background:
- Dystrophic epidermolysis bullosa (DEB) is a group of rare genetic blistering skin disorders.
- Accurate diagnosis is crucial for understanding disease mechanisms and developing targeted therapies.
Observation:
- Two patients with distinct DEB phenotypes underwent molecular diagnosis.
- A 45-year-old patient presented with severe generalized autosomal recessive DEB.
- A 4-month-old infant showed moderate DEB, primarily nail dystrophy.
Findings:
- The first patient had a splice site mutation (425-2 A>G) and a premature termination codon (c.553 C>T, p.R185X) in exon 5.
- The second patient had a heterozygous substitution (6100G>A, G2034R) affecting glycine to arginine conversion.
Implications:
- Molecular diagnosis is the definitive method for identifying DEB-causing mutations.
- Genotype-phenotype correlation enhances understanding of DEB pathogenesis.
- Molecular findings facilitate genetic counseling, prenatal diagnosis, and gene therapy development.
Abstract:
We identified the mutations in two patients with different phenotypes of dystrophic epidermolysis bullosa (DEB). We performed molecular diagnosis to a patient aged 45 years who showed the typical severe generalized autosomal recessive DEB signs when admitted to the hospital. The other patient is a 4-month-old boy who showed a moderate clinical aspect of DEB, dominated by nail dystrophy. The molecular diagnosis disclosed in the first patient the presence of a heterozygous mutation consisting of a nucleotide substitution that lead to a splice site mutation, namely 425-2 A>G, associated to a premature termination codon, in exon 5, namely c.553 C>T, p.R185X and in the second patient a heterozygous substitution at nucleotide position 6100 that converts a glycine amino acid to arginine (6100G>A). The mutation is designated G2034R. We conclude that molecular diagnosis is the conclusive EBD investigation, maps the phenotype of a patient with his genotype and thus allows a better understanding of the disease mechanism and the development of gene therapy. Molecular diagnosis also enables genetic counseling and prenatal diagnosis.
Related Concept Videos
Clinical Applications of Epidermal Stem Cells
Desmosomes
Healing II: Complications
Inflammatory Bowel Disease II: Ulcerative Colitis

